Karyopharm (KPTI) reports Q2 2026 financial results; myelofibrosis sNDA progress
Karyopharm (KPTI) reports second-quarter 2026 financial results and highlights continued progress toward a myelofibrosis sNDA submission, according to the company’s release.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.